Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY86(1) · pp.1 · 2020
- 피인용
- Web of Science 8Scopus 8
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 2.712
- ISSN
- 0378-6323
저자
- Raychaudhuri, Siba제1저자교신저자Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA
- Sarkar, SoumajyotiDivision of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA
- Panda, SaumyaDepartment of Dermatology, KPC Medical College, Kolkata, West Bengal
- 김병수Department of Dermatology, School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea;
- Raychaudhuri, Smriti교신저자VA Medical Center Sacramento, Mather, CA
- Ghosh, AsutoshDepartment of Critical Care Medicine, IPGME and R, Kolkata, West Bengal
초록
Anti-tumor necrosis factor-alpha (TNF-alpha) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis. However, a major concern is that patients receiving this therapy have an increased risk of infection, particularly of reactivation of latent tuberculosis (TB). There were an estimated 10.4 million new cases of tuberculosis in 2016, worldwide, and India has one of the largest TB case burden with an estimated incidence of 2.79 million cases of TB in the same year. Anti-TNF agents like etanercept and infliximab are available in India approved for psoriasis and psoriatic arthritis. But long-term use of these agents possesses a risk of reactivation of latent TB. In this review article, we assessed the risk of TB with anti-TNF therapy especially in patients with psoriasis and psoriatic arthritis in India. At the end of the article, we have also suggested a recommendation for screening of latent tuberculosis and its management, before starting anti-TNF-alpha therapy.
키워드
Anti-tumor necrosis factor agentslatent tuberculosispsoriasispsoriatic arthritisRHEUMATOID-ARTHRITISKOREAN PATIENTSINFLIXIMABINFECTIONINHIBITORSDIAGNOSIS
식별자
- Scopus EID
- 2-s2.0-85077175013
- WoS UID
- 000506395500001



로그인
연구물 목록으로